to be cynical about announcements of drugs that claim to slow the progress of Alzheimer’s disease, the most common form of
. Lecanemab, however, may be the real deal. Results of a clinical trial, conducted by its makers, Eisai, of Tokyo, and Biogen, of Cambridge, Massachusetts, have just been announced in the. After 18 months, it had slowed the progress of symptoms by a quarter. The trial involved 1,795 participants who were, crucially, in the early stages of the illness. Half received the drug. The others, a placebo. It showed two things. One was that modest but measurable slowing of progression. The other was that an explanation of Alzheimer’s called theBeta-amyloid is a protein which accumulates in plaques in the brains of those with Alzheimer’s. It, and a second protein, tau, are established signs of the illness.
This is a small first step. Some experts question whether the test used to show an improvement in symptoms is clinically meaningful. And lecanemab induced nasty side-effects—notably swelling and bleeding of the brain—in some participants. Also, diagnosing dementia this early is hard. Beta-amyloid can be detected by positron-emission tomography, but that requires a piece of expensive equipment.
* RIGHTEOUS!!… . That Is - AMMAZZING. .
Lecanemab will be the real deal.
Seriously? Half a percentage point between the placebo and those whom received treatment. I guess it’s slightly better than nothing 🤷♂️
biancavpimenta
la salud para ustedes es sólo un negocio... lamentable para la humanidad y su gente.
It causes cerebral hemorrhage and edema in a significant percentage of patients. Targeting amyloid is not targeting the underlying pathophysiology of Alzheimers
My grandfather forgets my name often…. Should we try to change this natural phenomenon? I feel it is the brain’s way of letting go of this earth… Very very difficult to watch, but I’m mixed feelings on a cure… thoughts?
The real BS is the cost per pop!
Underwhelming therapeutic effect — almost certainly it will have an overwhelming price tag
Magari prodotto dai vostri miserabili padroni parassiti.
One trial is enough for your investors to profit. It is not enough to prove a point. Or help patients. Your clients will be happy. What else matters to you?
Peter Thiel will be pleased.